Evolutionary history of MEK1 illuminates the nature of cancer and RASopathy mutations
E. P. Andrianova, R. A. Marmion, S. Y. Shvartsman, I. B. Zhulin
Abstract
Mutations in signal transduction pathways lead to various diseases including cancers. MEK1 kinase, encoded by the human MAP2K1 gene, is one of the central components of the MAPK pathway and more than a hundred somatic mutations in MAP2K1 gene were identified in various tumors. Germline mutations deregulating MEK1 also lead to congenital abnormalities, such as the Cardiofaciocutaneous Syndrome and Arteriovenous Malformation. Evaluating variants associated with a disease is a challenge and computational genomic approaches aid in this process. Establishing evolutionary history of a gene improves computational prediction of disease-causing mutations; however, the evolutionary history of MEK1 is not well understood. Here, by revealing a precise evolutionary history of MEK1 we construct a well-defined dataset of MEK1 metazoan orthologs, which provides sufficient depth to distinguish between conserved and variable amino acid positions. We used this dataset to match known and predicted disease-causing and benign mutations to evolutionary changes observed in corresponding amino acid positions. We found that all known and the vast majority of suspected disease-causing mutations are evolutionarily intolerable. We selected several MEK1 mutations that cannot be unambiguously assessed by automated variant prediction tools, but that are confidently identified as evolutionary intolerant and thus "damaging" by our approach, for experimental validation in Drosophila. In all cases, evolutionary intolerant variants caused increased mortality and severe defects in fruit fly embryos confirming their damaging nature predicted by out computational strategy. We anticipate that our analysis will serve as a blueprint to help evaluate known and novel missense variants in MEK1 and that our approach will contribute to improving automated tools for disease-associated variant interpretation. Significance StatementHigh-throughput genome sequencing has significantly improved diagnosis, management, and treatment of genetic diseases and cancers. However, in addition to its indisputable utility, genome sequencing produces many variants that cannot be easily interpreted - so called variants of uncertain significance (VUS). Various automated bioinformatics tools can help predicting functional consequences of VUS, but their accuracy is relatively low. Here, by tracing precise evolutionary history of each amino acid position in MEK1 kinase, mutations in which cause neurodegenerative diseases and cancer in humans, we can establish whether VUS seen in humans are evolutionarily tolerant. Using published data and newly performed experiments in an animal model, we show that evolutionarily tolerable variants in MEK1 are benign, whereas intolerable substitutions are damaging. Our approach will help in diagnostics of MEK1-associated diseases, it is generalizable to many other disease-associated genes, and it can help improving automated predictors.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The Cancermuts software package for the prioritization of missense cancer variants: a case study of AMBRA1 in melanoma
Matteo Tiberti, Luca Di Leo, … Elena Papaleo·Cell Death and DiseasePeer-reviewed·Oct 15, 2022
- A structure-based tool to interpret the significance of kinase mutations in clinical next generation sequencing in cancer
Amith Vikram Rangarajan, Ilona Sviezhentseva, … Beth Apsel Winger·Frontiers in OncologyPeer-reviewed·Aug 4, 2025
- Function and evolution of B-Raf loop dynamics relevant to cancer recurrence under drug inhibition
G. A. Babbitt, M. L. Lynch, … A. O. Hudson·bioRxiv·Jan 13, 2020
- Leveraging cancer mutation data to predict the pathogenicity of germline missense variants
Bushra Haque, David Cheerie, … Gregory Costain·medRxiv·Mar 11, 2024
- Global analysis of specificity determinants in eukaryotic protein kinases
D. Bradley, C. Vieitez, … P. Beltrao·bioRxiv·Aug 20, 2018
- Characterizing and comparing missense variants in monogenic disease and in cancer
Yizhou Yin, John Moult·bioRxiv·Jan 30, 2019